Desmoines News Desk

Chronic Hemodialysis Market to Exhibit Moderate Growth Rate till 2030, Investigates DelveInsight | Key Companies – Aronora, Novartis, Akebia Therapeutics, FibroGen, Astellas, and AstraZeneca

 Breaking News
  • No posts were found

Chronic Hemodialysis Market to Exhibit Moderate Growth Rate till 2030, Investigates DelveInsight | Key Companies – Aronora, Novartis, Akebia Therapeutics, FibroGen, Astellas, and AstraZeneca

January 11
19:40 2022
Chronic Hemodialysis Market to Exhibit Moderate Growth Rate till 2030, Investigates DelveInsight | Key Companies - Aronora, Novartis, Akebia Therapeutics, FibroGen, Astellas, and AstraZeneca
Delveinsight Business Research LLP
DelveInsight’s “Chronic hemodialysis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Chronic hemodialysis Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Chronic hemodialysis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Chronic hemodialysis Market

Chronic hemodialysis: An Overview

Hemodialysis is a treatment to filter wastes and water from the blood. It helps control blood pressure and balance important minerals, such as potassium, sodium, and calcium, in the blood. Patients with stage 5 chronic kidney disease (CKD), or kidney failure require hemodialysis in order to survive. Chronic (long-term) hemodialysis is capable of extending the life of patients who would otherwise die of uremia.

For patients with chronic kidney disease (CKD), the decision of when to start chronic dialysis is difficult because, although dialysis effectively treats the signs and symptoms of uremia and fluid overload (some of which may be life-threatening), it is a lifelong therapy that is associated with discomfort, inconvenience, and some risk for the patient. As a result, dialysis should be started when the benefit from relieving uremic signs and symptoms is thought to outweigh its risk and the associated effect on the quality of life, but not before this time.

Chronic hemodialysis Market Key Facts

According to the National Institute of Diabetes and Digestive and Kidney Diseases, more than 661,000 Americans have kidney failure. Of these, 468,000 individuals are on dialysis, and roughly 193,000 live with a functioning kidney transplant.

A nationwide US prospective cohort study of 1,041 patients found that the use of central venous catheters (CVCs) for hemodialysis was associated with a 50% higher adjusted risk of mortality, and a 41% higher risk of infection-related death, compared with the use of arteriovenous fistulas (AVFs).

Chronic hemodialysis Market 

Chronic hemodialysis market size is expected to increase during the forecast period owing to the launch of upcoming therapies in the market.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic hemodialysis market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Chronic hemodialysis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Get the PDF Sample of the Report:- Chronic hemodialysis Therapeutics Market

Chronic hemodialysis Epidemiology

The epidemiology section covers insights about the historical and current Chronic hemodialysis patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Chronic hemodialysis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic hemodialysis market or expected to get launched in the market during the study period. The analysis covers Chronic hemodialysis market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Chronic hemodialysis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Chronic hemodialysis Therapeutics Analysis

The emerging drugs landscape does not represent a particularly promising picture due to the lack of late-stage clinical products, which is quite evidently based on the scarcity of clinical trials being conducted. Current treatment aims to reduce symptoms and therapies targeting complications and comorbidities associated with chronic hemodialysis.

Some of the key Companies in the Chronic Hemodialysis Market Includes:

  • Aronora

  • Novartis’s

  • Akebia Therapeutics

  • FibroGen

  • Astellas

  • AstraZeneca

And many others.

Chronic hemodialysis Therapies covered in the report include:

  • AB023

  • AB002

  • CSJ137

  • Vadadustat

  • Roxadustat

And many more.

Get More Detailed Insights into the Emerging Therapies & Key Companies:- Chronic Insomnia Therapeutics Landscape

Table of Content

1. Key Insights

2. Executive Summary 

3. Chronic hemodialysis Competitive Intelligence Analysis

4. Chronic hemodialysis Market Overview at a Glance

5. Chronic hemodialysis Disease Background and Overview

6. Chronic hemodialysis Patient Journey

7. Chronic hemodialysis Epidemiology and Patient Population

8. Chronic hemodialysis Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic hemodialysis Unmet Needs

10. Key Endpoints of Chronic hemodialysis Treatment

11. Chronic hemodialysis Marketed Products

12. Chronic hemodialysis Emerging Therapies

13. Chronic hemodialysis Seven Major Market Analysis

14. Attribute Analysis

15. Chronic hemodialysis Market Outlook (7 major markets)

16. Chronic hemodialysis Access and Reimbursement Overview

17. KOL Views on the Chronic hemodialysis Market.

18. Chronic hemodialysis Market Drivers

19. Chronic hemodialysis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:- https://www.delveinsight.com/sample-request/chronic-hemodialysis-market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories